1. Aminoglycosides MDC. In: Brunton LL, Hilal-Dandal R, Knollmann BC, editors. Goodman & Gillman’s the pharmacological basis of therapeutics. 13th ed. New York: McGraw Hill; 2018. p. 1039–47.
2. Destache CJ. Aminoglycoside-induced nephrotoxicity - a focus on monitoring: a review of literature. J Pharm Pract. 2014;27(6):562–6.
3. Thummel KE, Shen DD, Isoherranen N. Design and optimization of dosage regimens: pharmacokinetic data. In: Brunton L, Chabner B, Knollman B, editors. Goodman & Gillman’s the pharmacological basis of therapeutics. 13th ed. New York: McGraw Hill; 2018. p. 1325–77.
4. Lietman PS, Smith CR. Aminoglycoside nephrotoxicity in humans. J Infect Dis. 1983;5(Suppl 2):S284–92.
5. de Jager P, van Altena R. Hearing loss and nephrotoxicity in long-term aminoglycoside treatment in patients with tuberculosis. Int J Tuberc Lung Dis. 2002;6(7):622–7.